Bayer: starts trial in chronic renal failure
(CercleFinance.com) - Bayer announced on Thursday the start of a Phase II clinical trial for the development of a new treatment for chronic renal failure.
The trial will evaluate the efficacy and safety of BAY3283142, a cyclic guanosine monophosphate (cGMP) stimulator, a mechanism that could pave the way for other therapeutic alternatives in the treatment of cardiovascular disease, the company says.
In so doing, the German pharmaceutical group intends to meet a major unmet medical need, since chronic renal failure is one of the world's top ten causes of death.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The trial will evaluate the efficacy and safety of BAY3283142, a cyclic guanosine monophosphate (cGMP) stimulator, a mechanism that could pave the way for other therapeutic alternatives in the treatment of cardiovascular disease, the company says.
In so doing, the German pharmaceutical group intends to meet a major unmet medical need, since chronic renal failure is one of the world's top ten causes of death.
Copyright (c) 2024 CercleFinance.com. All rights reserved.